Hull University Teaching Hospitals NHS Trust - Nuclear Medicine
Uncontrolled if printed
SOP Code | Title | Review Date |
---|---|---|
REF006 | Cardiac Amyloidosis Imaging Referral Criteria | 2027-07-08 |
Authorised By | Authorising Role | Authorisation Signature (only on master paper copy) | Date Authorised |
---|---|---|---|
Dr I Sunderji | ARSAC Licence Holder | 2024-07-08 |
See REF000 - Referring to Nuclear Medicine (HUTH) for details of how to refer.
Myocardial uptake of the radiotracer Technetium-99m-DPD has been validated and increasingly used in the non-biopsy diagnostic pathway of transthyretin related cardiac amyloidosis (ATTR). It offers a highly sensitive tool for detecting this disease and plays a key role in the non-invasive diagnostic workup of these patients[1]. However, it should be noted that DPD imaging is neither a primary tool to diagnose amyloid cardiomyopathy nor a tool to exclude cardiac amyloidosis on its own.
ARSAC Licence Holders | Indication |
---|---|
Prof Stephen Richard Underwood | cardiac amyloid imaging |
Dr Imran Sunderji | cardiac amyloid imaging |
Radiopharmaceutical | CT component of SPECT/CT | |
---|---|---|
Typical Radiation Dose (mSv) | 5.6 | 0.5 |
All UK registered practitioners
Sodium chloride for parenteral use (0.9% w/v).
Pregnancy